SUBSTITUTABILITY OF DRY POWDER INHALERS- A PERSPECTIVE FROM GERMAN PULMONOLOGISTS
Author(s)
Redeker M1, Schwarz E1, Mohrlang C1, Hellmann A2, Hering T3, Hering T4, Andres J3
1GlaxoSmithKline GmbH & Co. KG, München, Germany, 2Zentrum für Pneumologie, Onkologie und Schlafmedizin am Diako, Augsburg, Augsburg, Germany, 3Wissenschaftliches Netzwerk des Bundesverbandes der Pneumologen/BdP (WinPneu), Heidenheim, Germany, 4Lungenarztpraxis Tegel, Berlin, Germany
OBJECTIVES: Inhaled therapies can be substituted in German pharmacies unless prohibited through an “aut-idem-cross” by the physician. Substitution can lead to patients receiving unfamiliar inhalers resulting in problems with the application. This research aims to gain insights regarding German pulmonologists’ perspective and experience on substitutability including how often inhalers are the cause for therapy change. METHODS: RESULTS: CONCLUSIONS: Pulmonologists see patient individual selection of inhalers as crucial for a successful inhaled therapy and often exclude substitution. However, they assume that general practitioners do not commonly cross “aut-idem”. Prohibiting substitution of prescribed inhalers through national regulations may lead to less error rates and a better care for patients in Germany. Funded by GlaxoSmithKline. HO-15-16914.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMD119
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Health Care Research, Hospital and Clinical Practices
Disease
Respiratory-Related Disorders